Free Trial

Forte Biosciences Q3 2023 Earnings Report

Forte Biosciences logo
$6.58 -0.77 (-10.48%)
As of 04/3/2025 04:00 PM Eastern

Forte Biosciences EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Forte Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Forte Biosciences Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

Forte Biosciences Earnings Headlines

Forte Biosciences price target lowered to $61 from $64 at Chardan
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Forte Biosciences (FBRX) Gets a Buy from TD Cowen
See More Forte Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email.

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

View Forte Biosciences Profile

More Earnings Resources from MarketBeat